English
Implications of obesity and chronic degenerative diseases in complications from COVID-19: a systematic review
Article Sidebar
Main Article Content
Abstract
The aim of this work is to analyze studies related to metabolic comorbidities as obesity and chronic degenerative diseases (ECDs) and SARS-CoV-2 complications. A review with Pubmed search until May, 2020 using the keywords obesity, hypertension, diabetes, chronic degenerative diseases, COVID-19, SARS-CoV-2, angiotensin converting enzyme, and cytokine storm, was made. Studies indicate that different aspects related to the pathophysiology of obesity and ECDs promote complication on patient infected with SARS COv-2. In general, the chronic proinflammatory state on obese patient and the increase in the expression of ACE2 in subjects with hypertension and diabetes may enhance the infectious process including the systemic incorporation of the virus and promote higher imbalance in the immune response described as cytokine storm, with higher risk of mortality. Although the analysis is limited to few reports, with higher variation in the number of patients and descriptive datas, but it is clear that information generated up to the moment on Pandemic by COVID-19 will help to understand relations on obesity and ECDs in relation with complications by COVID-19. These are important for the therapeutic management of the patient, especially in Mexico where the prevalence of obesity and ECD are considerably higher.
Downloads
Article Details
Section
All articles published in the RECEIN Journal are under an open access policy and can be permanently free for everyone to read, download, copy and distribute according to the CC-BY license, except where otherwise noted.
How to Cite
References
Acevedo, M. (2006). Insulin resistance and hypertension I: mechanisms. Medwave, 6(6), e2305. http://doi.org/10.5867/medwave.2006.06.2305
Alifano, M., Alifano, P., Forgez, P., Iannelli, A. (2020). Renin-angiotensin system at the heart of COVID-19 pandemic. Biochimie,174, 30-33. http://doi.org/10.1016/j.biochi.2020.04.008
Andersen, C.J., Murphy, K.E., Fernandez, M.L. (2016). Impact of Obesity and Metabolic Syndrome on Immunity. Adv Nutr, 7(1), 66–75. http://doi.org/10.3945/an.115.010207
Ayala-Moreno, M.R., Vergara-Castañeda, A. (2017). Prevalencia del síndrome metabólico en población adulta. En: Panorama global del syndrome metabólico: diagnóstico y epidemiología. Ed. Académica Española (45-77).
Callahan, E.A. (2019). Current Status and Response to the Global Obesity Pandemic: Proceedings of a Workshop. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Roundtable on Obesity Solutions. National Academies Press (US) PMID: 31334935 NBK544128. http://doi.org/10.17226/25273
Chan, J.F., Kok, K.H., Zhu, Z., Chu, H., To, K.K., Yuan, S., et. al., (2020). Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect, 9(1), 221-236. http://doi.org/10.1080/22221751.2020.1719902
Costa de Lucena, T.M., Fernandes da Silva, S.A., de Lima, B.R., de Albuquerque, B.M.E., de Azevêdo, S.J. (2020). Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr, 14(4), 597–600. http://doi.org/10.1016/j.dsx.2020.05.025
Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature, 417(6891):822-828. doi:10.1038/nature00786.
De Chang, Lin M., Wei, L., Xie, L., Zhu, G., De la Cruz, C.S., et. al., (2020). Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA, 323(11), 1092-1093. http://doi.org/10.1001/jama.2020.1623
Encuesta Nacional de Salud y Nutrición (2018). Presentación de resultados. Instituto Nacional de Salud Pública. https://ensanut.insp.mx/encuestas/ensanut2018/doctos/informes/ensanut_2018_presentacion_resultados.pdf
Fang, L. y Karakiulakis, G. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet, 8, e21. http://doi.org/10.1016/S2213-2600(20)30116-8
Fernandez, C., Rysä, J., Almgren, P., Nilsson, J., Engström, G., Orho-Melander, M., et. al., (2018). Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med, 284:377–387. http://doi.org/10.1111/joim.12783
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.C., Turner, A.J., et. al., (2020) Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res, 126(10), 1456-1474. http://doi.org/10.1161/CIRCRESAHA.120.317015
Gil, A,, Olza, J., Gil-Campos, M., Gómez-Llorente, C., Aguilera, C.M. (2011). Is adipose tissue metabolically different at different sites? Int J Pediatr Obes, 6, 13-20.
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., Iotti, G., Latronico, N., Lorini, N., Merler, S., Natalini, G., Piatti, A., Ranieri, M.V., Scandroglio, A.M., Storti, E., Cecconi, M., Pesenti, A. (2020). Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA, 323(16), 1574–1581. http://doi.org/10.1001/jama.2020.5394
Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, Ch., He, J., et. al., (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 382, 1708-1720. http://doi.org/10.1056/NEJMoa2002032
Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E. (2013) Global estimates of diabetes prevalence for 2013 and projections for 2035. IDF Diabetes Atlas. Diabetes Res Clin Pract, 103(2), 137-49. http://doi.org/10.1016/j.diabres.2013.11.002
Hodgson, K., Morris, J., Bridson, T., Govan, B., Rush, C., Ketheesan, N. (2015). Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology, 144, 171–185. http://doi.org/10.1111/imm.12394
Instituto Nacional de Estadística y Geografía (INEGI). Reporte de casuas de mortalidad 2019. https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2019/EstSociodemo/
Magrone, T., Magrone, M. y Jirillo, E. (2020). Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective [Epub ahead of print]. Endocr Metab Immune Disord Drug Target,. http://doi.org/10.2174/1871530320666200427112902
Merad, M. y Martin, J.C. (2020). Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol, 20, 355–362. http://doi.org/10.1038/s41577-020-0331-4
Muniyappa, R. y Gubbi, S. (2020). COVID-19 Pandemic, Coronaviruses, and Diabetes Mellitus. Am J Physiol Endocrinol Meta, 318(5), E736-E741. http://doi.org/10.1152/ajpendo.00124.2020
Ni, L,. Ye, F., Cheng, M.L., Feng, Y., Deng, Y.O., Zhao, H., et. al., (2020). Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity, S2,1-7. http://doi.org/10.1016/j.immuni.2020.04.023
Organización Mundial de la Salud (2020). Coronavirus disease (COVID-19) Pandemic. Weekly Epidemiological and Operational updates September 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Ponce-Gutiérrez, Y., Ponce-Gutiérrez, A. (2012). El sistema renina-angiotensina desde la circulación hasta la célula: implicaciones más allá de la hipertensión. CorSalud (Revista de Enfermedades Cardiocasculares) 4(4), 287-293.
Roca-Ho, H., Riera, M., Palau, V., Pascual, J. y Soler, M.J. (2017). Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. Int J Mol Sci, 18(3), 563. http://doi.org/10.3390/ijms18030563
South, A.M., Diz, D.I. y Chappell, M.C. (2020). Perspectives integrative cardiovascular physiology and pathophysiology covid-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physio, 318, H1084–H1090. http://doi.org/10.1152/ajpheart.00217.2020
Tanaka, S., Inoue, S., Isoda, F., Waseda, M., Ishihara, M., Yamakawa, T., et. al., (1993). Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord, 17(11), 631-636.
UNICEF, México. Informe: Sobrepeso y obesidad en niños y niñas y doalescentes. https://www.unicef.org/mexico/sobrepeso-y-obesidad-en-ni%C3%B1os-ni%C3%B1as-y-adolescentes
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J.V.J., Pfeffer, M.A., et. al., (2020). Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med, 382(17), 1653-1659. http://doi.org/10.1056/NEJMsr2005760
Wan, Y., Shang, J., Graham, R., Baric, R.S. y Lia, F. (2020). Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol, 94(7), e00127-20. http://doi.org/10.1128/JVI.00127-20
Wang, D., Bo, H., Hu, Ch., Zhu, F., Liu, X., Zhang, J., et. al., (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA, 323(11), 1061-1069. http://doi.org/10.1001/jama.2020.1585
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., et. al., (2020). Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis, 94, 91-95. http://doi.org/10.1016/j.ijid.2020.03.017
Yang, X., Yu, Y., Xu, J., Pu, K., Chen, Z., Guo, Qinghong., et. al., (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020, Feb 24. http://doi.org/10.1016/S2213-2600(20)30079-5
Ye, Q., Wang, B., Mao, J. (2020). The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect, 80(6), 607–613. http://doi.org/10.1016/j.jinf.2020.03.037